Foundation directory
Scott R Mackenzie Foundation Inc Grants
Private foundation · EIN 46-3383293 · IRS 990-PF filings through tax year 2024
- Total grants paid
- $2.2M
- Grants reported
- 11
- Median grant
- $149.6K
- Future commitments
- None reported
Giving by tax year
| Tax year | Grants paid | Amount |
|---|---|---|
| 2024 | 5 | $960.9K |
| 2023 | 6 | $1.2M |
Where Scott R Mackenzie Foundation Inc gives
States of grant recipients reported on the foundation's 990-PF filings, by dollars received.
Largest reported grants
The biggest individual grants on file, as reported by the foundation to the IRS.
| Recipient | Location | Purpose | Tax year | Amount |
|---|---|---|---|---|
| MOUNT DESERT ISLAND BIOLOGICAL LABORATORY | BAR HARBOR, ME | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO CONTINUE THE PROJECT AWARDED IN 2022 TO ESTABLISH A NOVEL TREATMENT STRATEGY FOR DIABETIC KIDNEY DISEASE. PREVIOUS SUPPORT FROM THE MACKENZIE FOUNDATION IS ALLOWING MDI BIO LAB TO UNDERSTAND THE STRUCTURE AND FUNCTIONAL PARTS OF THE HPA2 MOLECULE AND ESTABLISH A BASELINE FROM WHICH TO FULLY UNDERSTAND ITS FUNCTION. BASED ON THIS ONGOING WORK, MDI BIO LAB NOW SEEKS TO INVESTIGATE THE EFFECT OF DIABETES IN A MODEL ORGANISM OF AGING (AFRICAN TURQUOISE KILLIFISH). SIMULTANEOUSLY, MDI BIO LAB ALSO PROPOSES TO USE THIS MODEL TO STUDY THE LOSS OF PERITUBULAR CAPILLARIES OBSERVED DURING KIDNEY AGING. | 2023 | $450K |
| MOUNT DESERT ISLAND BIOLOGICAL LABORATORY | BAR HARBOR, ME | THIS PROJECT SEEKS TO CONTINUE THE PROJECT AWARDED IN 2022 TO ESTABLISH A NOVEL TREATMENT STRATEGY FOR DIABETIC KIDNEY DISEASE. PREVIOUS SUPPORT FROM THE MACKENZIE FOUNDATION IS ALLOWING MDI BIO LAB TO UNDERSTAND THE STRUCTURE AND FUNCTIONAL PARTS OF THE HPA2 MOLECULE AND ESTABLISH A BASELINE FROM WHICH TO FULLY UNDERSTAND ITS FUNCTION. BASED ON THIS ONGOING WORK, MDI BIO LAB NOW SEEKS TO INVESTIGATE THE EFFECT OF DIABETES IN A MODEL ORGANISM OF AGING (AFRICAN TURQUOISE KILLIFISH). SIMULTANEOUSLY, MDI BIO LAB ALSO PROPOSES TO USE THIS MODEL TO STUDY THE LOSS OF PERITUBULAR CAPILLARIES OBSERVED DURING KIDNEY AGING. | 2024 | $450K |
| EMORY UNIVERSITY GRANTS | ATLANTA, GA | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO OPTIMIZE AND VALIDATE A COMPUTATIONAL PATHOLOGY-BASED IMAGE RISK PREDICTOR (OVARISC) THAT PREDICTS OUTCOME AND RESPONSE IN ADVANCED OCA RECEIVING PRIMARY PLATINUM-BASED COMBINATION CHEMOTHERAPY, AND TO CONFIRM THE ASSOCIATION BETWEEN OVARISC SCORES AND RESPONSE TO ICI ON A BLINDED VALIDATION SET OBTAINED FROM AN INDEPENDENT CLINICAL TRIAL. | 2023 | $250K |
| HMH HOSPITALS CORPORATION | EDISON, NJ | YEAR 2 FUNDING - THIS PROJECT SEEKS TO FOCUS ON QUANTIFYING SELECTIVE PRESSURES APPLIED BY NUCLEOTIDE DEPLETION AND GENOMIC STRESS IN ORDER TO DISSECT THE EVOLUTIONARY DYNAMICS OF CANCER CELLS ACROSS MULTIPLE TUMOR TYPES, INCLUDING LEUKEMIA, LYMPHOMA, MYELOMA, COLORECTAL CANCER, MELANOMA, AND RETINOBLASTOMA. | 2024 | $150K |
| HMH HOSPITALS CORPORATION | EDISON, NJ | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO FOCUS ON QUANTIFYING SELECTIVE PRESSURES APPLIED BY NUCLEOTIDE DEPLETION AND GENOMIC STRESS IN ORDER TO DISSECT THE EVOLUTIONARY DYNAMICS OF CANCER CELLS ACROSS MULTIPLE TUMOR TYPES, INCLUDING LEUKEMIA, LYMPHOMA, MYELOMA, COLORECTAL CANCER, MELANOMA, AND RETINOBLASTOMA. | 2023 | $150K |
| UNIVERSITY OF FLORIDA FOUNDATION | GAINESVILLE, FL | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO IDENTIFY DEPENDENCIES OF TUMOR CELLS IN DEEP MARGINS BY PERFORMING SINGLE-CELL SEQUENCING ON LARGER COHORT OF TUMORS THE GRANTEE COLLECTED (N=28) AND TESTING THEIR FINDINGS IN MODEL SYSTEMS. THUS, THE STUDY WOULD OPEN NEW AVENUES FOR THERAPIES TARGETING SPECIFIC TRAITS WITHIN TUMOR CELLS DRIVING RECURRENCE, AND FOR IMPROVED STRATEGIES RELEASING THE HOST IMMUNE SYSTEM AGAINST GLIOBLASTOMA. | 2023 | $149.6K |
| UNIVERSITY OF FLORIDA FOUNDATION | GAINESVILLE, FL | YEAR 2 FUNDING - THIS PROJECT SEEKS TO IDENTIFY DEPENDENCIES OF TUMOR CELLS IN DEEP MARGINS BY PERFORMING SINGLE-CELL SEQUENCING ON LARGER COHORT OF TUMORS THE GRANTEE COLLECTED (N=28) AND TESTING THEIR FINDINGS IN MODEL SYSTEMS. THUS, THE STUDY WOULD OPEN NEW AVENUES FOR THERAPIES TARGETING SPECIFIC TRAITS WITHIN TUMOR CELLS DRIVING RECURRENCE, AND FOR IMPROVED STRATEGIES RELEASING THE HOST IMMUNE SYSTEM AGAINST GLIOBLASTOMA. | 2024 | $149.3K |
| UNIVERSITY OF FLORIDA FOUNDATION | GAINESVILLE, FL | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO SEEK TO DEFINE TREATMENT REGIMENS OF BLOOD THINNING MEDICATIONS ASSOCIATED WITH REDUCED RISK OF RECURRENT HEART ATTACKS, WHICH MAY INCLUDE THE USE OF THE MORE POTENT BLOOD THINNER TICAGRELOR ALSO IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE. | 2023 | $125K |
| UNIVERSITY OF FLORIDA FOUNDATION | GAINESVILLE, FL | YEAR 2 FUNDING - THIS PROJECT SEEKS TO DEFINE TREATMENT REGIMENS OF BLOOD THINNING MEDICATIONS ASSOCIATED WITH REDUCED RISK OF RECURRENT HEART ATTACKS, WHICH MAY INCLUDE THE USE OF THE MORE POTENT BLOOD THINNER TICAGRELOR ALSO IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE. | 2024 | $125K |
| UNIVERSITY OF MIAMI COLLEGE OF MEDICINE | CORAL GABLES, FL | YEAR 2 FUNDING - THIS PROJECT SEEKS TO UTILIZE GENERATIVE ADVERSARIAL NETWORK (GAN) MODELS TO CREATE HIGH-QUALITY SYNTHETIC IMAGES REPRESENTING VARIOUS PROSTATE CANCER (PCA) GRADES. THESE IMAGES WILL BE TAILORED TO ACCOUNT FOR THE MORPHOLOGICAL AND GENOMIC GRANULARITY ASSOCIATED WITH EACH GLEASON GRADE WHILE REQUIRING SIGNIFICANTLY SMALLER TRAINING DATA SAMPLES. PRELIMINARY DATA INDICATES THAT THIS APPROACH CONSIDERABLY ENHANCES AI MODELS' PROGNOSTIC CAPABILITIES FOR PCA. | 2024 | $86.6K |
| UNIVERSITY OF MIAMI COLLEGE OF MEDICINE | CORAL GABLES, FL | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO UTILIZE GENERATIVE ADVERSARIAL NETWORK (GAN) MODELS TO CREATE HIGH-QUALITY SYNTHETIC IMAGES REPRESENTING VARIOUS PROSTATE CANCER (PCA) GRADES. THESE IMAGES WILL BE TAILORED TO ACCOUNT FOR THE MORPHOLOGICAL AND GENOMIC GRANULARITY ASSOCIATED WITH EACH GLEASON GRADE WHILE REQUIRING SIGNIFICANTLY SMALLER TRAINING DATA SAMPLES. PRELIMINARY DATA INDICATES THAT THIS APPROACH CONSIDERABLY ENHANCES AI MODELS' PROGNOSTIC CAPABILITIES FOR PCA. | 2023 | $77.9K |
How to apply
This foundation publishes application instructions on its latest 990-PF and does not report restricting giving to preselected organizations. See more foundations that accept applications.
- Contact
- CAROLYN TUCKER EXECUTIVE DIRECTOR
- Address
- PO BOX 550750 JACKSONVILLE, FL, 322550750
- Phone
- 8558166858
- INFO@SCOTTRMACKENZIEFOUNDATION.COM
- Deadlines
- INITIAL GRANT APPLICATION: APRIL 30TH; FINAL GRANT APPLICATION: JUNE 30TH
- Application materials
- AN ELIGIBLE 501(C)(3) ORGANIZATION CAN GO TO WWW.SCOTTRMACKENZIEFOUNDATION.COM AND FOLLOW THE INSTRUCTIONS FOR APPLYING FOR A GRANT.
- Restrictions
- FUNDING IS AVAILABLE FOR AMERICAN-BASED ORGANIZATIONS WITH A MISSION TO FIND A CURE FOR: CANCER LUNG DISEASE (INCLUDING ASTHMA) DIABETES HEART DISEASE
About this data
Figures are aggregated from Scott R Mackenzie Foundation Inc's IRS Form 990-PF electronic filings (2 filings on file, most recent tax year 2024). Totals reflect grants the foundation reported as paid, and can lag the current year because foundations file annually and often on extension. Source: IRS 990-PF e-file archive.